ABEONA THERAPEUTICS INC. (ABEO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 4M 8M 12M Q3 '13: 189K Q4 '13: 162K Q1 '14: 208K Q2 '14: 247K Q3 '14: 236K Q4 '14: 234K Q1 '15: 258K Q2 '15: 282K Q3 '15: 285K Q4 '15: 215K Q1 '16: 235K Q2 '16: 214K Q3 '16: 184K Q4 '16: 256K Q1 '17: 186K Q2 '17: 217K Q3 '17: 219K Q4 '17: 215K Q1 '18: 531K Q2 '18: 276K Q3 '18: 1.7M Q4 '18: 482K Q1 '19: 0 Q2 '19: 0 Q3 '20: 7M Q4 '20: 3M Q1 '22: 346K Q2 '22: 1M Q3 '22: 0 Q4 '22: 68K Q1 '23: 0 Q2 '23: 3.5M Q3 '23: 0 Q4 '23: 0 Q1 '25: 0 Q2 '25: 400K Q3 '25: 0 Q4 '25: 5.4M Q1 '26: 8.7M Q2 '26: 11.4M Q3 '14 Q4 '15 Q1 '17 Q2 '18 Q3 '20 Q4 '22 Q1 '25 Q2 '26

Gross Profit Quarterly

-2.5M 0 2.5M 5M 7.5M Q3 '25: -488K Q4 '25: 4.4M Q1 '26: 6M Q2 '26: 7.2M Q3 '25 Q4 '25 Q1 '26 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '16: -5.2M Q4 '16: -5.8M Q1 '17: -5.3M Q2 '17: -8.4M Q3 '17: -5.4M Q4 '17: -8.8M Q1 '18: -10.7M Q2 '18: -12.6M Q3 '18: -16.9M Q4 '18: -18M Q1 '19: -19.1M Q2 '19: -24M Q3 '19: -17.6M Q4 '19: -16.4M Q1 '20: -48.2M Q2 '20: -12.5M Q3 '20: -6.2M Q4 '20: -14.5M Q1 '21: -14.6M Q2 '21: -13.7M Q3 '21: -14.9M Q4 '21: -46.7M Q1 '22: -20.6M Q2 '22: -8M Q3 '22: -9.4M Q4 '22: -12.9M Q1 '23: -12M Q2 '23: -10.6M Q3 '23: -11.3M Q4 '23: -13.2M Q1 '24: -14.3M Q2 '24: -17.9M Q3 '24: -15.3M Q4 '24: -16.7M Q1 '25: -19.7M Q2 '25: -22.8M Q3 '25: -24M Q4 '25: -22.9M Q1 '26: -23M Q2 '26: -13.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-80M -40M 0 40M 80M 120M Q3 '16: -2.6M Q4 '16: -7M Q1 '17: -5.2M Q2 '17: -8.3M Q3 '17: -5.3M Q4 '17: -8.4M Q1 '18: -10.5M Q2 '18: -12.2M Q3 '18: -16.4M Q4 '18: -17.5M Q1 '19: -18.6M Q2 '19: -23.9M Q3 '19: -17.4M Q4 '19: -16.4M Q1 '20: -48.2M Q2 '20: -13M Q3 '20: -7.2M Q4 '20: -15.8M Q1 '21: -16M Q2 '21: -15.2M Q3 '21: -7M Q4 '21: -46.7M Q1 '22: -22M Q2 '22: -4.1M Q3 '22: -6.4M Q4 '22: -7.1M Q1 '23: -9.1M Q2 '23: -16.7M Q3 '23: -11.8M Q4 '23: -16.6M Q1 '24: -31.6M Q2 '24: 7.4M Q3 '24: -30.3M Q4 '24: -9.3M Q1 '25: -12M Q2 '25: 108.8M Q3 '25: -5.2M Q4 '25: -20.5M Q1 '26: -17.1M Q2 '26: -20.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 1.5M 3M 4.5M Q3 '25: 488K Q4 '25: 1M Q1 '26: 2.7M Q2 '26: 4.2M Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '16: -4M Q4 '16: -3.4M Q1 '17: -5.9M Q2 '17: -5M Q3 '17: -6.8M Q4 '17: -5M Q1 '18: -4.1M Q2 '18: -9M Q3 '18: -9M Q4 '18: -17M Q1 '19: -15.1M Q2 '19: -15.2M Q3 '19: -18.3M Q4 '19: -14.2M Q1 '20: -13.2M Q2 '20: -9.5M Q3 '20: -10.7M Q4 '20: -1.6M Q1 '21: -13.6M Q2 '21: -11.5M Q3 '21: -10.3M Q4 '21: -30.3M Q1 '22: -13.7M Q2 '22: -9M Q3 '22: -6.8M Q4 '22: -14M Q1 '23: -11.7M Q2 '23: -10.3M Q3 '23: -5.7M Q4 '23: -9.2M Q1 '24: -14.5M Q2 '24: -12.7M Q3 '24: -12.2M Q4 '24: -16.6M Q1 '25: -18.4M Q2 '25: -18.8M Q3 '25: -21.2M Q4 '25: -18M Q1 '26: -19.8M Q2 '26: -17.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '16: -4.1M Q4 '16: -3.4M Q1 '17: -5.9M Q2 '17: -5M Q3 '17: -6.8M Q4 '17: -5.8M Q1 '18: -7.6M Q2 '18: -12.4M Q3 '18: -10.7M Q4 '18: -17.6M Q1 '19: -16.3M Q2 '19: -19.3M Q3 '19: -19.2M Q4 '19: -14.4M Q1 '20: -13.7M Q2 '20: -10M Q3 '20: -11M Q4 '20: -1.6M Q1 '21: -14M Q2 '21: -11.5M Q3 '21: -10.7M Q4 '21: -33.5M Q1 '22: -13.8M Q2 '22: -9M Q3 '22: -6.8M Q4 '22: -14M Q1 '23: -12M Q2 '23: -10.3M Q3 '23: -5.8M Q4 '23: -9.3M Q1 '24: -15.3M Q2 '24: -13.4M Q3 '24: -12.6M Q4 '24: -17.2M Q1 '25: -19.8M Q2 '25: -21.7M Q3 '25: -23.7M Q4 '25: -19.1M Q1 '26: -20.7M Q2 '26: -18M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q2 '10: 27.9M Q1 '11: 19.2M Q2 '11: 19.4M Q1 '12: 24.1M Q2 '12: 24.2M Q3 '12: 24.2M Q1 '13: 25.2M Q2 '13: 25.5M Q3 '13: 508.7K Q1 '14: 25.9M Q2 '14: 26.2M Q3 '14: 532.3K Q1 '21: 94.2M Q2 '21: 3.9M Q3 '21: 3.9M Q1 '22: 5.8M Q2 '22: 5.8M Q3 '22: 6.4M Q1 '23: 16.9M Q2 '23: 18M Q3 '23: 24.8M Q1 '24: 27.3M Q2 '24: 51.2M Q3 '24: 48.1M Q1 '25: 49.8M Q2 '25: 66.6M Q3 '25: 54.2M Q1 '26: 56.6M Q2 '26: 57M Q2 '10 Q2 '12 Q3 '13 Q1 '21 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q1 '13: -0.17 Q2 '13: 0.32 Q4 '15: -0.51 Q1 '16: -0.58 Q2 '16: -0.62 Q3 '16: -0.51 Q4 '16: -0.64 Q1 '17: -0.60 Q2 '17: -0.61 Q3 '17: -0.66 Q4 '17: -0.66 Q1 '18: -0.75 Q2 '18: -0.80 Q3 '18: -1.01 Q4 '18: -1.18 Q1 '19: -1.35 Q2 '19: -1.58 Q3 '19: -1.59 Q4 '19: -1.53 Q1 '20: -1.66 Q2 '20: -1.31 Q3 '20: -1.04 Q4 '20: -0.91 Q1 '21: -0.56 Q3 '22: -3.90 Q4 '22: -5.53 Q1 '23: -2.27 Q2 '23: -4.55 Q3 '23: -4.03 Q4 '23: -2.58 Q1 '24: -3.20 Q2 '24: -2.54 Q3 '24: -2.69 Q4 '24: -2.19 Q1 '25: -1.27 Q2 '25: 0.70 Q3 '25: 1.23 Q4 '25: 1.01 Q1 '26: 0.95 Q2 '26: -1.11 Q2 '16 Q3 '17 Q4 '18 Q1 '20 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.